{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:47:10Z","timestamp":1785890830227,"version":"3.56.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00357857"],"award-info":[{"award-number":["RS-2024-00357857"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KBRI funded by the Ministry of Science, ICT & Future Planning","award":["26-BR-02-04, 26-BR-05-01, and 26-BR-06-01"],"award-info":[{"award-number":["26-BR-02-04, 26-BR-05-01, and 26-BR-06-01"]}]},{"name":"Korea Dementia Research Project through the Korea Dementia Research Center","award":["RS-2024-00343370"],"award-info":[{"award-number":["RS-2024-00343370"]}]},{"name":"NIPA (National IT Industry Promotion Agency) to support digital medical devices for AI-based Neurodevelopmental disorders","award":["H0501-25-1001"],"award-info":[{"award-number":["H0501-25-1001"]}]},{"name":"NRF","award":["RS-2026-25492172"],"award-info":[{"award-number":["RS-2026-25492172"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We recently demonstrated that abemaciclib treatment modulates cognitive function, Alzheimer's disease (AD) pathology, and neuroinflammatory responses in wild-type mice treated with lipopolysaccharide and in 5xFAD mice. In this study, we investigated the influence of abemaciclib treatment on neuroinflammation and cognitive function in 6- or 9-month-old PS19 mice, a P301S mutant tauopathy model. We found that abemaciclib administration suppressed microglial activation in 6-month-old PS19 mice, whereas astrocytic activation was partially attenuated in the entorhinal cortex but not in the hippocampus. In addition, abemaciclib treatment improved short-term and recognition memory and the dendritic spine formation in 6- and 9-month-old PS19 mice. More importantly, abemaciclib administration enhanced short-term and recognition memory in a DYRK1A-dependent manner in 6-month-old PS19 mice. Collectively, our results suggest that abemaciclib treatment alleviates neuroinflammatory responses and cognitive impairment through DYRK1A in 6- or 9-month-old human tau transgenic PS19 mice, highlighting how this multi-kinase-targeting drug could be leveraged for the treatment of neurodegenerative diseases.<\/jats:p>","DOI":"10.1186\/s13041-026-01318-x","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:55:10Z","timestamp":1780314910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The CDK4\/6 inhibitor abemaciclib attenuates cognitive impairment and neuroinflammation via DYRK1A in human tau transgenic mice"],"prefix":"10.1186","volume":"19","author":[{"given":"Hyun-ju","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyang-Sook","family":"Hoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"1318_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.31887\/DCNS.2013.15.4\/hjahn","volume":"15","author":"H Jahn","year":"2013","unstructured":"Jahn H. Memory loss in Alzheimer\u2019s disease. Dialogues Clin Neurosci. 2013;15:445\u201354.","journal-title":"Dialogues Clin Neurosci"},{"key":"1318_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS. Amyloid-beta and Tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505\u20138.","journal-title":"JAMA Neurol"},{"key":"1318_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2018;4:575\u201390.","journal-title":"Alzheimers Dement (N Y)"},{"key":"1318_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines7040097","author":"KG Yiannopoulou","year":"2019","unstructured":"Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou SH. Reasons for failed trials of disease-modifying treatments for Alzheimer Disease and their contribution in recent research. Biomedicines. 2019. https:\/\/doi.org\/10.3390\/biomedicines7040097.","journal-title":"Biomedicines"},{"key":"1318_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/DDDT.S137783","volume":"12","author":"SP Corona","year":"2018","unstructured":"Corona SP, Generali D. Abemaciclib: a CDK4\/6 inhibitor for the treatment of HR+\/HER2- advanced breast cancer. Drug Des Devel Ther. 2018;12:321\u201330.","journal-title":"Drug Des Devel Ther"},{"key":"1318_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26935-z","volume":"12","author":"IH Kaltheuner","year":"2021","unstructured":"Kaltheuner IH, Anand K, Moecking J, Duster R, Wang J, Gray NS, et al. Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation. Nat Commun. 2021;12:6607.","journal-title":"Nat Commun"},{"key":"1318_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106725","volume":"190","author":"HJ Lee","year":"2023","unstructured":"Lee HJ, Hoe HS. Inhibition of CDK4\/6 regulates AD pathology, neuroinflammation and cognitive function through DYRK1A\/STAT3 signaling. Pharmacol Res. 2023;190:106725.","journal-title":"Pharmacol Res"},{"key":"1318_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202513135","volume":"13","author":"J Han","year":"2026","unstructured":"Han J, Jeong JH, Lee D, Jung Y, Jin Y, Jung ES, et al. Dual targeting of Tau kinases and autophagy by Abemaciclib independent of CDK4\/6 inhibition. Adv Sci (Weinh). 2026;13:e13135.","journal-title":"Adv Sci (Weinh)"},{"key":"1318_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther. 2023;8:359.","journal-title":"Signal Transduct Target Ther"},{"key":"1318_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481\u20137.","journal-title":"Nature"},{"key":"1318_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","volume":"25","author":"MT Heneka","year":"2025","unstructured":"Heneka MT, van der Flier WM, Jessen F, Hoozemanns J, Thal DR, Boche D, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2025;25:321\u201352.","journal-title":"Nat Rev Immunol"},{"key":"1318_CR12","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1096\/fj.07-104539","volume":"22","author":"F Liu","year":"2008","unstructured":"Liu F, Liang Z, Wegiel J, Hwang YW, Iqbal K, Grundke-Iqbal I, et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 2008;22:3224\u201333.","journal-title":"FASEB J"},{"key":"1318_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","volume":"278","author":"J Wegiel","year":"2011","unstructured":"Wegiel J, Gong CX, Hwang YW. The role of DYRK1A in neurodegenerative diseases. FEBS J. 2011;278:236\u201345.","journal-title":"FEBS J"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13041-026-01318-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-026-01318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-026-01318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:44:23Z","timestamp":1785887063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13041-026-01318-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1186\/s13041-026-01318-x","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental procedures were approved by the institutional biosafety committee (IBC) and performed in accordance with approved animal protocols of the Korea Brain Research Institute (KBRI, approval no. IACUC-22-00015).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"60"}}